# US 8,771,698 B2 · Modulation of UL24 interactions with protein targets and uses thereof for inhibition of herpesvirus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,698 B2
- Document ID: US8771698B2
- Status: Granted
- Kind: B2
- Application number: 13/661,212
- Filed: 2012-10-26
- Published: 2013-05-02
- Granted: 2014-07-08
- Earliest claimed: 2011-10-27
- Assignees: Institut National De La Recherche Scientifique
- Applicants: Institut National de la Recherche Scientifique
- Inventors: Angela Pearson; Luc Bertrand
- Web page: https://patentgrep.com/patent/US8771698B2

## CPC

- A61K 38/162: {from virus}
- A61K 38/1709: {from mammals}
- A61P 31/22: for herpes viruses
- C07K 16/087: Herpes simplex virus
- C12Q 1/18: Testing for antimicrobial activity of a material
- G01N 33/56994: {Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus}
- A61K 2039/505: {comprising antibodies}
- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and uses for the treatment of herpesvirus infection based on the inhibition of the interaction between herpesvirus UL24 and non-muscle myosin type IIa (NM2a) are described.

## Claims

### Claim 1

A method for determining whether an agent may be useful for inhibiting the interaction between herpesvirus UL24 and non-muscle myosin type IIa (NM2a), wherein said method comprises contacting the UL24 polypeptide of SEQ ID NO:2 and the NM2a polypeptide of SEQ ID NO:4 in the presence of said agent, and determining whether the interaction between said UL24 and NM2a polypeptides is inhibited in the presence of said agent, wherein inhibition of the interaction between said UL24 and NM2a polypeptides in the presence of said agent is indicative that said agent may be useful for inhibiting the interaction between UL24 and NM2a.

### Claim 2 (depends on 1)

The method of claim 1, wherein said UL24 polypeptide and/or said NM2a polypeptide are expressed in an isolated cell.

### Claim 3 (depends on 2)

The method of claim 2, wherein said isolated cell is an isolated cell transfected or transformed with (i) a nucleic acid encoding said UL24 polypeptide of SEQ ID NO:2; (ii) a nucleic acid encoding said NM2a polypeptide of SEQ ID NO:4; or (iii) both (i) and (ii).